Results 131 to 140 of about 7,948,396 (393)

Identification of functional and diverse circulating cancer‐associated fibroblasts in metastatic castration‐naïve prostate cancer patients

open access: yesMolecular Oncology, EarlyView.
Cancer‐associated fibroblasts (CAFs) promote cancer growth, invasion (metastasis), and drug resistance. Here, we identified functional and diverse circulating CAFs (cCAFs) in patients with metastatic prostate cancer (mPCa). cCAFs were found in higher numbers and were functional and diverse in mPCa patients versus healthy individuals, suggesting their ...
Richell Booijink   +6 more
wiley   +1 more source

CET Research Brief #2 June 2017 [PDF]

open access: yes, 2017
Inside this issue: --High School Chemistry Teachers’ Views of Engineering Inclusion Before and After a Professional Development Program by Sarah B.
University of Northern Iowa. Center for Educational Transformation.
core   +1 more source

High-throughput dataset of impurity adsorption on common catalysts in biomass upgrading applications

open access: yesScientific Data
An extensive dataset consisting of adsorption energies of pernicious impurities present in biomass upgrading processes on common catalysts and support materials has been generated.
Michelle A. Nolen   +4 more
doaj   +1 more source

Cohort profile: the National Congenital Anomaly Registration Dataset in England

open access: yesBMJ Open
Purpose The National Congenital Anomaly and Rare Disease Registration Service (NCARDRS), part of National Disease Registration Service in National Health Service England, quality assures, curates and analyses individual data on the pregnancies, fetuses ...
Danielle Martin   +12 more
doaj   +1 more source

Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells

open access: yesMolecular Oncology, EarlyView.
In the era of immunotherapies, many patients either do not respond or eventually develop resistance. We propose to pave the way for proteomic analysis of surface‐expressed proteins called surfaceome, of circulating tumor cells. This approach seeks to identify immune evasion mechanisms and discover potential therapeutic targets. Circulating tumor cells (
Doryan Masmoudi   +3 more
wiley   +1 more source

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

open access: yesMolecular Oncology, EarlyView.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker   +14 more
wiley   +1 more source

Center for Educational Transformation, Research and Development Center Annual Report, October 10, 2016 [PDF]

open access: yes, 2016
The annual report of the Center for Educational Transformation at the University of Northern Iowahttps://scholarworks.uni.edu/cetcommunications/1002/thumbnail ...
University of Northern Iowa. Center for Educational Transformation.
core   +1 more source

How much is invested in obesity prevention in Australia? An analysis of major research and Federal Government funding, 2013–2022

open access: yesPublic Health Research & Practice
Objective and importance of study: Overweight and obesity are the second leading risk factors for death and non-communicable disease in Australia. This study aimed to examine the Australian Federal Government funding landscape for population-level ...
Huong Ngoc Quynh Tran   +6 more
doaj   +1 more source

Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors – a biomarker analysis of the ALICE and ICON trials

open access: yesMolecular Oncology, EarlyView.
In this explorative biomarker analysis, we assessed serial sampling of circulating tumor cells (CTCs) with CellSearch in two randomized trials testing immune checkpoint inhibitors (ICIs) in metastatic breast cancer. Our data demonstrate a prognostic potential of CTCs, most apparent 4 weeks into ICI therapy.
Nikolai Kragøe Andresen   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy